Is Kopran Ltd (KOPRAN) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Kopran Ltd is a average quality company .

Is Kopran Ltd (KOPRAN) undervalued or overvalued?

The key valuation ratios of Kopran Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Kopran Ltd (KOPRAN) share price return in the past 10 years?

Kopran Ltd share price has appreciated 11.9% annually (CAGR) over the past ten years.

Is Kopran Ltd (KOPRAN) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Kopran Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

What is the share price of Kopran Ltd (KOPRAN)?

Company share prices are keep on changing according to the market conditions. The current trading price of Kopran Ltd (KOPRAN) on 17-Apr-2026 16:59:59 at 16:59 is 159.60.

What is the market cap of Kopran Ltd (KOPRAN)?

Market capitalization is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 17-Apr-2026 at 16:59, the market cap of Kopran stood at Rs. 770.64 Cr.

What is the P/E ratio of Kopran?

The latest standalone P/E ratio of Kopran as of 17-Apr-2026 is 38.05.

What is the P/B ratio of Kopran Ltd (KOPRAN)?

The latest standalone P/B ratio of Kopran Ltd (KOPRAN) as of 17-Apr-2026 is 1.80.

What is the 52-week high and low of Kopran Ltd (KOPRAN)?

The 52-week high of Kopran Ltd (KOPRAN) is Rs. 212.50 and the 52-week low is Rs. 107.00.

What is the TTM revenue of Kopran Ltd (KOPRAN)?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kopran is Rs. 263.54 (Cr.).

Kopran Ltd (KOPRAN) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Kopran Ltd (KOPRAN)
Brand: Kopran

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	9.5%	9.5%	5.3%	8.7%	8%	13.6%	5.6%	9.4%	11.4%	8.6%	-
Value Creation Index ⓘ	-0.3	-0.3	-0.6	-0.4	-0.4	0.0	-0.6	-0.3	-0.2	-0.4	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	187	182	154	197	179	223	205	273	337	271	264
Sales YoY Gr.	-	-3.1%	-15.3%	27.9%	-8.8%	24.3%	-8.2%	33.5%	23.6%	-19.7%	-
Adj EPS ⓘ	2.8	0.6	0	3.1	2.6	4.1	1.8	6.4	6.6	5.2	4.2
YoY Gr.	-	-77.8%	-96.8%	15250%	-14%	54.2%	-54.8%	249.5%	1.9%	-21.2%	-
BVPS (₹) ⓘ	43.5	46.5	47.6	50.5	53.1	57.1	78.6	82.1	86.3	89	88.7
Adj Net Profit ⓘ	12.1	2.7	0.1	13.3	11.4	17.6	8.9	31	31.6	24.9	20
Cash Flow from Ops. ⓘ	18.7	4.2	12.5	11.8	10	48.8	-37.8	16.9	35	23.3	-
Debt/CF from Ops. ⓘ	1.8	13.4	4.2	4.2	4.6	0.3	-1	1.7	0.7	1.9	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	4.2%	8.6%	9.8%	-19.7%
Adj EPS ⓘ	7.1%	14.3%	41%	-21.2%
BVPSⓘ	8.3%	10.9%	4.3%	3.2%
Share Price	11.9%	4.4%	1.9%	-21.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	6.3	1.4	0	6.3	5.1	7.4	2.8	8	7.8	5.9	4.7
Op. Profit Mgn % ⓘ	13.3	9.6	4.7	11.8	13.1	13.5	7.5	10.4	10.9	14.3	13.4
Net Profit Mgn % ⓘ	6.4	1.5	0.1	6.8	6.4	7.9	4.3	11.4	9.4	9.2	7.7
Debt to Equity ⓘ	0.2	0.3	0.3	0.2	0.2	0.1	0.1	0.1	0.1	0.1	-
Working Cap Days ⓘ	267	188	233	186	229	187	236	231	204	255	156
Cash Conv. Cycle ⓘ	2	25	48	42	84	55	87	83	73	110	74

Recent Performance Summary

Net Profit is growing at healthy rate in last 3 years 41.02%

Return on Equity has declined versus last 3 years average to 4.70%

Sales growth has been subdued in last 3 years 9.84%

Sales growth is not so good in last 4 quarters at -6.14%

	Standalone	Consolidated
TTM EPS (₹)	4.2	3.4
TTM Sales (₹ Cr.)	264	620
BVPS (₹) ⓘ	88.7	105.7
Reserves (₹ Cr.) ⓘ	380	462
P/BV ⓘ	1.80	1.51
PE ⓘ	38.05	46.58

From the Market
52 Week Low / High (₹)	107.00 / 212.50
All Time Low / High (₹)	6.40 / 558.84
Market Cap (₹ Cr.)	771
Equity (₹ Cr.)	48.3
Face Value (₹)	10
Industry PE ⓘ	42.1

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	187	182	154	197	179	223	205	273	337	271
Operating Expenses ⓘ +	162	164	146	174	156	193	189	245	301	232
Manufacturing Costs	22	26	28	30	29	31	37	39	45	46
Material Costs	103	95	77	102	86	121	107	156	205	131
Employee Cost	16	19	18	20	20	18	21	25	26	30
Other Costs ⓘ	22	24	23	21	21	23	25	25	25	25
Operating Profit ⓘ	25	17	7	23	23	30	15	28	37	39
Operating Profit Margin (%)	13.3%	9.6%	4.7%	11.5%	12.9%	13.5%	7.5%	10.2%	10.9%	14.3%
Other Income ⓘ +	1	9	10	3	2	10	8	16	17	6
Exceptional Items ⓘ	-1	0	0	0	0	0	0	0	0	0
Interest ⓘ	10	10	7	5	6	4	3	3	5	4
Depreciation ⓘ	3	3	3	3	3	4	4	4	5	5
Profit Before Tax ⓘ	11	13	7	17	16	33	16	37	45	36
Tax ⓘ	0	5	2	4	5	9	4	6	10	9
Profit After Tax	11	9	5	13	11	23	12	31	35	27
PAT Margin (%)	6.1%	4.7%	3.1%	6.6%	6.3%	10.5%	5.7%	11.4%	10.3%	9.9%
Adjusted EPS (₹)	2.6	2.0	1.1	3.0	2.6	5.4	2.4	6.5	7.2	5.6
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	28%	123%	46%	42%	54%

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	197	201	206	218	230	247	379	396	416	430
Share Capital ⓘ	52	43	43	43	43	43	48	48	48	48
Reserves ⓘ	145	158	162	175	186	204	331	347	368	382
Debt +	29	50	45	41	36	16	37	28	23	45
Long Term Debt	22	28	22	22	10	2	2	2	2	4
Short Term Debt	7	22	24	19	27	13	35	26	20	41
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	36	36	29	32	32	40	30	62	52	46
Others Liabilities ⓘ	18	19	17	24	28	22	19	20	21	25
Total Liabilities ⓘ	279	306	297	316	326	324	464	506	511	546
Fixed Assets
Net Fixed Assets ⓘ +	35	39	38	42	43	47	46	47	52	61
Gross Block	83	43	45	51	56	65	68	73	82	97
Accumulated Depreciation	48	3	7	10	13	17	21	26	30	35
CWIP ⓘ	0	4	8	7	7	3	3	4	5	7
Investments ⓘ	156	157	157	158	158	159	259	260	261	263
Inventories	28	25	30	25	41	28	42	48	49	56
Trade Receivables	20	38	20	45	42	49	59	84	88	92
Cash Equivalents	4	2	2	1	1	3	3	3	7	21
Others Assets ⓘ	35	40	42	39	33	35	52	61	48	46
Total Assets ⓘ	279	306	297	316	326	324	464	506	511	546

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	19	4	12	12	10	49	-38	17	35	23
PBT ⓘ	11	13	7	17	16	33	16	37	45	36
Adjustment ⓘ	13	16	6	3	12	7	4	-9	3	7
Changes in Working Capital ⓘ	-6	-24	3	-5	-14	14	-55	-5	-2	-9
Tax Paid ⓘ	-0	-1	-3	-4	-4	-5	-4	-6	-10	-10
Cash Flow From Investing Activity ⓘ +	-4	-9	-2	-4	1	-9	-100	10	-6	-15
Capex	-5	-12	-5	-6	-5	-4	-3	-6	-10	-17
Net Investments	-1	0	0	0	0	-2	0	0	0	0
Others ⓘ	3	3	4	1	5	-2	-97	16	4	2
Cash Flow From Financing Activity ⓘ +	-15	5	-11	-7	-11	-40	138	-26	-24	6
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	126	0	0	1
Net Proceeds from Borrowing ⓘ	0	-14	0	-0	-0	-9	0	0	-0	2
Interest Paid ⓘ	-10	-10	-7	-5	-6	-4	-3	-3	-5	-4
Dividend Paid ⓘ	0	0	0	0	0	-6	-6	-14	-14	-14
Others ⓘ	-5	28	-4	-2	-5	-20	21	-9	-5	21
Net Cash Flow ⓘ	0	-0	-0	-0	0	0	-0	1	5	14

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	6.52	4.37	2.31	6.12	5.01	9.85	3.75	8.07	8.54	6.35
ROCE (%)	9.45	9.5	5.28	8.67	7.98	13.57	5.64	9.44	11.36	8.63
Asset Turnover Ratio	0.68	0.62	0.51	0.64	0.56	0.69	0.52	0.56	0.66	0.51
PAT to CFO Conversion(x)	1.73	0.44	2.4	0.92	0.91	2.13	-3.17	0.55	1	0.85
Working Capital Days
Receivable Days	47	58	69	60	89	75	97	96	93	121
Inventory Days	41	53	65	51	68	56	62	60	53	71
Payable Days	128	137	154	109	134	106	119	107	102	136

About Kopran Ltd

The company was incorporated on April 26, 1958 as a private limited company under the name Kopran Chemical Company Pvt. Ltd. by Ramanlal V Shah Sevantilal, A Shah , Chimanlal G Sheth and Jivanalal M Shah. In 1972, the companyâ€™s management was acquired by Chemo Pharma Laboratories Ltd and the Companyâ€™s products were marketed by them.

Promoted by the Parijat Enterprises, Kopran is currently an integrated health care company. Kopran has used research-based technology to contribute towards total health-care. The company started modestly as a Semi Synthetic Penicillin (SSP) player and expanded to becomes the largest SSP Player in India with an annual SSP facility of over 1200 tones per annum.Subsequently the SSP business was hived off into a separate Company in a joint venture with Synpac Pharmaceuticals Ltd, UK.Kopran Laboratories Ltd. markets and supports high-tech life-saving medical equipments and diagnostics reagents since 1988.

Kopran Research Laboratories Ltd. (KRLL) is an emerging research organisation with particular interests in the areas of drug discovery, polymer technology and synthesis of new molecules.

Kopran is working towards creating and maintaining a global presence.Presence in Africa through Kampala Pharmaceutical Industries (KPI),a pharmaceutical company engaged in the manufacture and marketing of finished dosage forms in Uganda.

The company is having presence in the Middle East Market through a joint venture with Dubai Investment Corporation a leading investment company in Dubai for the manufacture and marketing of finished dosage forms in Dubai.

KRLL is a 100% subsidiary of Kopran Ltd. KRLL is recognised by the Department of Science and Industrial Research (DSIR), Government of India. The company is staffed with competent and dedicated team of scientists.

Product range of the company includes:

Finished Dosage Forms

Antibiotics/antibacterials
Anti-malarial
Cadiovasculars
Pain management
Anthelminthics
Antiprotozoals
Antidiabetics
Gastrointestinals
Drug for erectile dysfuntion
Antiallergics
Respiratory/anti-asthmatics
Metered dose inhalers
Dry powder inhalers
Antiviral

Active Pharmaceutical Ingredients

Anti-hypertensives
Macrolides
Taste Masked
Cephalosporins
Under Development
Others

Achievements/ recognition:

Kopran has a state of art manufacturing plants (Penicillin & General) approved by: -MCC (South Africa) -TGA, Australia and FDA, USA are in the pipeline

Future plans:

Brand Equity Development
Research for New Chemical Entities
Globalise its operations thus making Kopran a truly International Pharmaceutical Company.

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Kopran Ltd (KOPRAN) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Kopran Share Price